Short-Term Stocks with Analyst Upgrades and Strong Upside Potential

 bullish.beats
 
  bullish.beats
 
Follow  Message
 
 
 
Streaking.Winners tracks stocks achieving consecutive gains, focusing on consistent performers and market momentum to keep investors informed.
 

•  06 Dec 2025
 

•   ACHR  
   
  0.00%
•   ADBE  
   
  0.00%
•   ASTL  
   
  0.00%
•   ASTS  
   
  0.00%
•   BE  
   
  0.00%

$HRTG Heritage Insurance HRTG has experienced a remarkable 136% YTD surge, driven by disciplined underwriting and reinsurance-fueled margin gains. At a current price of $26.73, analysts see potential for the stock to climb to $63.08. Offers the most attractive near-term opportunity with significant upside

$BNTC Benitec Biopharma trades at $13.58 with an analyst target of $25.46, implying an 87.5% upside. While price targets alone may not fully capture market dynamics, consensus upgrades in earnings estimates suggest favorable momentum. Promising upside, though less certain than HRTG

$PROF Profound Medical currently sits at $6.60, with a target price of $12.04, indicating an 82.4% potential gain. Earnings estimate revisions point to a near-term positive trend, yet liquidity remains modest. Attractive upside, particularly for speculative traders

$EPRX Eupraxia Pharmaceuticals offers a 77% upside from $6.28 to $11.12, fueled by positive Phase 2b trial results. With solid analyst sentiment and increasing investor interest, the stock may continue climbing if clinical outcomes support its pipeline. Strong upside potential, suited for biotech-focused traders

$PGY Pagaya Technologies has a potential 64% gain, with current price $24.83 and target $40.72. The stocks downtrend and modest liquidity suggest cautious optimism, but positive earnings revisions indicate room for recovery. Moderate upside opportunity, but trend caution advised

$TEAM Atlassian is trading at $159.33 with a $239.68 target, representing 50.4% upside. Analysts agree on potential growth despite mixed efficacy of price targets. The large-cap software stocks stability and earnings upgrades support a measured bullish case. Worth considering for balanced portfolios, though upside is moderate

$LLY Eli Lilly shows a 35% upside from $1010.31 to $1363.92. Options activity suggests strategic positioning ahead of significant catalysts. With a strong uptrend and solid fundamentals, it is a high-conviction pick for near-term growth. Offers meaningful upside with solid institutional support

$CXM Sprinklr trades at $7.79, with a $10.35 target implying 32.9% upside. Analyst sentiment is favorable, but the sideways trend and relatively modest momentum call for selective positioning. Limited near-term upside relative to higher-potential names

$HIMX Himax Technologies at $9.07 has a target of $11.97, suggesting a 32% gain. Focus on AR technology and analyst backing provides moderate growth prospects, although volatility may persist. Moderate opportunity, but not the highest upside

$ENGN enGene Holdings sits at $8.07 with a target of $10.57, reflecting a 31% upside. Positive trial results and analyst optimism support continued gains in the near term. Small-cap biotech with moderate upside potential

$ACHR Archer Aviation trades at $8.60, with a $11.16 target (29.7%). Despite analyst optimism, the sideways trend and early-stage market exposure suggest higher risk/reward. Speculative near-term play with limited upside

$MLYS Mineralys Therapeutics has a 27.6% upside from $38.50 to $49.11. While analysts see growth, earnings visibility remains limited. Moderate upside, suitable for selective trading

$PTC offers 26.3% upside to $219.17 from $173.52. Analysts support its AR growth, but the downtrend calls for caution. Modest near-term upside, trend needs monitoring

$SNAP trades at $7.91 with a $9.91 target (25.3% upside). Mixed sentiment among analysts tempers the potential, but AR strategy remains promising. Limited upside relative to biotech or insurance leaders

$USAR USA Rare Earth at $17.22 could climb 25% to $21.53. The rare earth supply deal underpins bullish momentum. Solid niche opportunity with manageable risk

$PATH UiPath trades at $18.67 with a target of $23.34, implying 25% upside. Strong earnings performance fuels an ongoing uptrend. Moderate upside, trend supportive

$TFPM Triple Flag Precious Metals shows 23% upside from $32.75 to $40.28. Positive analyst outlook and recent fiscal performance make it a steady pick. Good near-term opportunity within the precious metals sector

$ASTS climbs 18% with a target of $87.23. Strong momentum supports a bullish thesis but consider volatility around launches. Upside exists, but consider volatility around launches

$CP Canadian Pacific trades at $73.76, with an $87 target (+18%). Down from all-time highs, the stock is positioned for value-based recovery. Moderate upside, lower-risk blue-chip play

$FLNC Fluence has 17% upside to $28.03 from $23.96, supported by analyst upgrades. Momentum is positive but limited relative to higher-potential biotech or insurance stocks. Small near-term gain potential

$RGTI Rigetti Computing trades at $28.11 with a $32.33 target (14.6% upside). Optimism around interest rate cuts fuels recent rallies, though the trend remains down. Speculative with modest near-term upside

$BE Bloom Energy at $119.18 targets $137 (+15%). Market optimism mirrors the stocks recovery, providing steady but limited gains. Mild upside; better for conservative exposure

$EOSE Eos Energy offers 15% upside to $17.24 from $14.99. Bargain-hunting and a recovering energy sector support the trend. Limited upside relative to top performers

$QBTS D-Wave Quantum at $27 with a $30.78 target offers 14.6% upside. Government contracts support growth, but near-term potential is modest. Small upside; niche speculative play

$ASTL Algoma Steel trades at $4.15 with a $4.48 target (8% upside). Layoffs and operational challenges cap upside potential. Limited opportunity: high caution advised

$ADBE Adobe shows 5% potential upside to $363.57 from $346.26. Solid fundamentals but already valued near highs. Minimal near-term upside; more suited for long-term investors

View All Headlines